Back to Search
CATHERINE PISANO, MD
MD
MOHS-Micrographic Surgery Physician
NPI: 1467986828IndividualAccepts Medicare
Specialties, Licenses & Credentials
MOHS-Micrographic Surgery PhysicianPrimary
Dermatology — MOHS-Micrographic Surgery
Code: 207ND0101X
33936(NH)
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
CMS Specialties
PrimaryDERMATOLOGY
Education
LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE IN NEW ORLEANS
Class of 2017
Research & Publications (20)
Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.
PMID 19179095·Crit Rev Oncol Hematol·2009
8-other
Optimized synthesis and enhanced efficacy of novel triplex-forming camptothecin derivatives based on gimatecan.
PMID 19309124·Bioconjug Chem·2009
8-other
Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells.
PMID 19276160·Mol Cancer Ther·2009
4-observational
Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
PMID 19084294·Eur J Med Chem·2009
8-other
N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors.
PMID 19285395·Bioorg Med Chem Lett·2009
4-observational
Fine-needle cytology of metastatic endometrioid neoplasms: experience with eight cases.
PMID 19191293·Diagn Cytopathol·2009
5-case
A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial.
PMID 19266200·Cancer Chemother Pharmacol·2009
3-trial
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
PMID 19039248·Oncology·2009
3-trial
Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors.
PMID 19359173·Bioorg Med Chem Lett·2009
8-other
Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968.
PMID 18645015·Mol Cancer Ther·2008
7-preclinical
A potent integrin antagonist from a small library of cyclic RGD pentapeptide mimics including benzyl-substituted azabicycloalkane amino acids.
PMID 18770516·ChemMedChem·2008
8-other
Novel A-ring and B-ring modified combretastatin A-4 (CA-4) analogues endowed with interesting cytotoxic activity.
PMID 18783207·J Med Chem·2008
7-preclinical
Metastases to the breast: role of fine needle cytology samples. Our experience with nine cases in 2 years.
PMID 18048381·Ann Oncol·2008
8-other
Intracellular accumulation and DNA damage persistence as determinants of human squamous cell carcinoma hypersensitivity to the novel camptothecin ST1968.
PMID 18445521·Eur J Cancer·2008
7-preclinical
The tubulin-depolymerising agent combretastatin-4 induces ectopic aster assembly and mitotic catastrophe in lung cancer cells H460.
PMID 18386182·Apoptosis·2008
8-other
Synthesis and biological activity of fluorinated combretastatin analogues.
PMID 18396857·J Med Chem·2008
7-preclinical
E-ring-modified 7-oxyiminomethyl camptothecins: Synthesis and preliminary in vitro and in vivo biological evaluation.
PMID 18424133·Bioorg Med Chem Lett·2008
8-other
A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
PMID 18243011·Crit Rev Oncol Hematol·2008
3-trial
Atypical retinoids ST1926 and CD437 are S-phase-specific agents causing DNA double-strand breaks: significance for the cytotoxic and antiproliferative activity.
PMID 18790775·Mol Cancer Ther·2008
7-preclinical
Triplex formation on DNA targets: how to choose the oligonucleotide.
PMID 18954091·Biochemistry·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 3 locations total
- Address
- 1500 Red River St
Austin, TX 78701 - Phone
- (504) 512-3247
Quick Facts
- NPI
- 1467986828
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 4
- Locations
- 3
- Years in Practice
- 9
- Publications
- 20
Are you this provider?
Claim Your Profile